Biotech companies still run on press releases and poster abstracts that reach the same 200 people every time. The companies winning mindshare in 2026 build content engines that get found by investors, physicians, and partners searching on their own – including in AI answer tools, not just Google.
The Problem
Press releases and abstracts aren't content strategy
Most biotech companies confuse clinical communications with content marketing. Press releases announce milestones. Conference abstracts present data to peers. Neither builds the sustained narrative that keeps your company visible between major announcements. When your only content is event-driven, you go dark for investors and physicians for months at a stretch, and someone else fills that silence.
Regulatory fear kills content velocity
Medical-legal review built for promotional materials gets applied to educational content by default, and output slows to near zero. Competitors publish weekly thought leadership while your blog posts sit in MLR for six weeks. The line between promotional claims and educational content is clear in regulation but blurred in practice inside most biotech teams, and that ambiguity is what's costing you visibility.
Technical depth without commercial framing wastes expert time
Your CSO can explain the science beautifully to another scientist. Translating that into content that moves investors evaluating market size, hospital administrators weighing adoption, and payers assessing value takes commercial framing most biotech teams never build. You end up with content that impresses conference peers and generates zero commercial pipeline.
How We Help
We start by auditing your existing content against three audiences: investors, physicians, and commercial partners. We map what exists, what's missing, and where competitors are building mindshare that should belong to you. Almost every biotech company we look at has deep clinical content and zero commercial content strategy – the gap is never data, it's translation.
From there we build a content architecture organized by audience and buying stage, the same discipline behind our broader growth strategy work applied to a regulated category. Investor content covers market opportunity, competitive differentiation, and commercial readiness, published on a schedule that holds attention between funding rounds instead of only around raise events. Physician content puts your science in clinical practice context so there's familiarity in place before commercial launch. Partner content demonstrates platform potential and makes the case for collaboration on its own terms.
Execution runs on a regulatory-compliant workflow, not a workaround. We split content into educational and promotional tracks with review paths sized to the risk: thought leadership moves through streamlined scientific-accuracy review, while anything making specific claims goes through full MLR. Our team writes and edits; your experts review for accuracy, not tone. That split is what lets you publish weekly instead of quarterly.
Measurement ties content back to commercial outcomes, not traffic. We track investor engagement – deck requests, meetings that follow content exposure – physician awareness through KOL engagement and conference follow-up quality, and partnership interest. Increasingly that also means checking whether your company shows up when someone asks an AI tool about your therapeutic category, since that's now a real discovery path for investors and physicians doing early research. Page views tell you nothing about any of this.
What we deliver
- Content strategy framework – audience-segmented editorial calendar with a built-in regulatory workflow
- Thought leadership program – executive-authored content that positions your leadership team as category authorities
- Investor content series – market analysis, competitive positioning, and commercial vision pieces timed between raises
- Physician education content – clinical-context pieces that build familiarity with your approach before launch
The biotech companies that commercialize fastest aren't the ones with the best data – they're the ones who spent two years building the narrative before the data matured. Content marketing is how you win the market before you win the trial.
Our Methodology
Our 90-day content sprint for biotech starts with audience mapping and regulatory workflow design. Phase one identifies content gaps across investor, physician, and partner audiences, audits what competitors are publishing, and maps the topics your company should own. We also design the review workflow up front – separating educational content on a fast-track from promotional content on full MLR – because that split, not a lack of ideas, is what kills most biotech content programs before they start.
Phase two moves into editorial production. We build templates per audience segment, set a publishing cadence, and produce the first wave of content. Your experts give us 30-minute interviews; we turn those into polished thought leadership so the time cost on your side stays low.
Phase three scales production and locks in measurement. By month three you should have a working content engine producing 4-8 pieces a month across segments. We track engagement quality, not vanity metrics, connecting content exposure to investor meetings, KOL conversations, and partnership inquiries – and increasingly, whether your company surfaces in AI-generated answers on your therapeutic area.
How We Work
Content marketing engagements for biotech companies typically run 6-12 months. The first 30 days are strategy, audience research, and regulatory workflow design – we interview your leadership, review competitor content, and lock in the editorial framework and compliance process before anything gets published.
Days 31-90 are the production ramp. We produce initial content across priority audience segments while refining the editorial process in real time. Your subject matter experts sit for brief interviews, 30-45 minutes each, that we develop into full articles, whitepapers, and thought leadership. This is also when the regulatory review workflow gets stress-tested and adjusted.
Months 4-12 are steady-state production with ongoing optimization. Cadence stabilizes at 4-8 pieces a month. We keep adjusting the mix across investor, physician, and partner content based on what's actually driving engagement and where your commercial priorities are shifting.
Weekly editorial check-ins keep production on schedule. Monthly reviews look at content performance against commercial metrics. Quarterly deep-dives reassess audience priorities and the competitive content landscape – a category that moves faster than most biotech teams have bandwidth to track on their own.
- Investor mindshare – consistent visibility between funding rounds that supports valuation momentum
- Physician familiarity – pre-launch awareness that shortens the runway to commercial adoption
- Content velocity – a sustainable publishing cadence that survives regulatory review instead of stalling in it
If your biotech & pharma company needs content marketing leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does content marketing cost for biotech companies?
Monthly retainers typically run $15K-$35K depending on content volume, how many audience segments you're covering, and production complexity. That covers strategy, writing, editing, regulatory workflow management, and performance analytics. A comparable in-house team – writer, editor, strategist – runs $300K or more a year in fully loaded cost, so a fractional engagement gets you coverage across all three audiences for a fraction of that.
How do you handle regulatory review without killing content velocity?
We build parallel review tracks from day one instead of forcing everything through one lane. Educational and thought leadership content goes through a streamlined scientific-accuracy check. Content making specific claims goes through full medical-legal review. That split is standard regulatory practice, not a shortcut, and it's what lets you publish educational content weekly while promotional materials still get full sign-off. Most clients see a meaningful jump in publishing velocity within the first 60 days.
How long before content marketing produces measurable results for biotech?
Engagement improvements show up in 60-90 days – sharper investor meeting prep, more inbound interest from target physicians, growing organic visibility. Commercial pipeline influence becomes measurable around the 6-month mark. The real payoff compounds over 12-18 months, once your thought leadership library is deep enough to work across every commercial conversation without starting from scratch each time.
What makes Winston Francois different from healthcare content agencies?
Most healthcare content agencies produce content that's technically accurate and commercially inert – correct, and useless for moving a deal or a physician relationship forward. We build content around commercial outcomes: investor meetings, physician awareness, partnership conversations. Our team pairs life science fluency with growth marketing experience, so every piece serves a specific business objective instead of just filling a calendar slot.
How do you measure content marketing ROI in biotech?
We track audience-specific engagement: investor deck requests and meeting conversions, physician content consumption and KOL engagement rates, partnership inquiry quality. We also watch organic search visibility and, increasingly, how often your company gets cited when someone asks an AI tool about your category. Page views are secondary to the actual conversations content generates.
What type of biotech company is the right fit for this service?
Series A through commercial-stage companies with a clear therapeutic thesis and at least one audience that needs sustained engagement – investors between rounds, physicians ahead of launch, or partners evaluating your platform. If you're pre-Series A with no clinical data yet, content marketing is premature. The first move is a content audit to see where your current positioning has gaps across those audiences.
